Madrigal Pharmaceuticals (NASDAQ:MDGL) Sets New 52-Week Low at $81.01

Share on StockTwits

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL)’s share price reached a new 52-week low on Thursday . The company traded as low as $81.01 and last traded at $81.69, with a volume of 334 shares changing hands. The stock had previously closed at $83.05.

MDGL has been the subject of a number of recent analyst reports. ValuEngine lowered shares of Madrigal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 4th. BidaskClub lowered shares of Madrigal Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday. Cowen restated a “buy” rating on shares of Madrigal Pharmaceuticals in a research report on Tuesday, November 12th. UBS Group upgraded shares of Madrigal Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price target for the company from $125.00 to $127.00 in a research report on Thursday, January 9th. Finally, Svb Leerink restated an “outperform” rating on shares of Madrigal Pharmaceuticals in a research report on Thursday, January 2nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company’s stock. Madrigal Pharmaceuticals presently has an average rating of “Buy” and an average price target of $155.50.

The company has a market capitalization of $1.19 billion, a P/E ratio of -17.50 and a beta of 1.05. The business’s fifty day moving average price is $92.55 and its 200-day moving average price is $94.06.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.03. During the same quarter in the prior year, the company earned ($0.56) EPS. On average, research analysts forecast that Madrigal Pharmaceuticals Inc will post -5.1 earnings per share for the current fiscal year.

In other news, major shareholder Bay City Capital Llc sold 1,200,000 shares of Madrigal Pharmaceuticals stock in a transaction on Friday, December 13th. The shares were sold at an average price of $105.47, for a total transaction of $126,564,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 47.69% of the company’s stock.

A number of institutional investors have recently bought and sold shares of MDGL. Tower Research Capital LLC TRC bought a new stake in Madrigal Pharmaceuticals in the third quarter worth $41,000. Metropolitan Life Insurance Co NY increased its position in shares of Madrigal Pharmaceuticals by 17.9% during the third quarter. Metropolitan Life Insurance Co NY now owns 2,668 shares of the biopharmaceutical company’s stock valued at $230,000 after buying an additional 406 shares during the period. Jane Street Group LLC increased its position in shares of Madrigal Pharmaceuticals by 7.8% during the second quarter. Jane Street Group LLC now owns 2,523 shares of the biopharmaceutical company’s stock valued at $265,000 after buying an additional 183 shares during the period. Cubist Systematic Strategies LLC increased its position in shares of Madrigal Pharmaceuticals by 82.5% during the second quarter. Cubist Systematic Strategies LLC now owns 2,716 shares of the biopharmaceutical company’s stock valued at $285,000 after buying an additional 1,228 shares during the period. Finally, Squarepoint Ops LLC purchased a new position in shares of Madrigal Pharmaceuticals during the third quarter valued at about $336,000. 62.05% of the stock is owned by institutional investors and hedge funds.

About Madrigal Pharmaceuticals (NASDAQ:MDGL)

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia.

Further Reading: S&P/ASX 200 Index

Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

LSV Asset Management Has $18.86 Million Stock Position in Kite Realty Group Trust
LSV Asset Management Has $18.86 Million Stock Position in Kite Realty Group Trust
Global Net Lease Inc  Shares Acquired by LSV Asset Management
Global Net Lease Inc Shares Acquired by LSV Asset Management
LSV Asset Management Reduces Stock Position in Hyster-Yale Materials Handling Inc
LSV Asset Management Reduces Stock Position in Hyster-Yale Materials Handling Inc
LSV Asset Management Boosts Holdings in Cadence Bancorp
LSV Asset Management Boosts Holdings in Cadence Bancorp
LSV Asset Management Buys 629,038 Shares of Corcept Therapeutics Incorporated
LSV Asset Management Buys 629,038 Shares of Corcept Therapeutics Incorporated
LSV Asset Management Has $22.18 Million Stake in Eagle Pharmaceuticals Inc
LSV Asset Management Has $22.18 Million Stake in Eagle Pharmaceuticals Inc


© 2006-2020 Ticker Report